Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.62 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.51 |
| ▸ | WIZ | O95785 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17552859 | 0.85 | CRBN (0.69) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL24319331 | 0.85 | CRBN (0.69) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL25996067 | 0.83 | CRBN (0.69) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL22828005 | 0.83 | CRBN (0.65) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL22566723 | 0.83 | IKZF2 (0.65) | CRBNIKZF2WIZ | |
| SCHEMBL30851278 | 0.83 | CRBN (0.69) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL19503638 | 0.83 | CRBN (0.65) | CRBNIKZF2CSNK1A1IKZF1 | |
| SCHEMBL25988439 | 0.82 | CRBN (0.70) | CRBNIKZF2WIZ | |
| SCHEMBL24816729 | 0.82 | CRBN (0.64) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL21621742 | 0.82 | CRBN (0.58) | CRBNIKZF2WIZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CRBN 1/4885IKZF2 1770/4885CSNK1A1 339/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | CRBN 3/4885IKZF2 1554/4885CSNK1A1 947/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | CRBN 1/4885IKZF2 467/4885CSNK1A1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.